Vasculitis and Blood Vessel Inflammation During Immunotherapy
Vasculitis during immunotherapy is inflammation of the blood vessels caused by an overactive immune response to checkpoint-inhibitor treatment. It is rare, but because blood vessels supply every organ, it can affect the skin, joints, nerves, kidneys or heart at once — so a new rash with fever, numbness, or unexplained organ symptoms is checked the same day, not watched over a few days.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Rare, but multi-organ — vasculitis can affect skin, joints, nerves, kidneys or heart together, unlike most irAEs which target one organ.
- Easy to miss early — a new rash, joint pain or mild numbness can look unrelated until they're seen together.
- Fast-moving when severe — kidney, nerve or heart-vessel involvement can worsen within days if it isn't reported.
- Manageable when caught early — most cases respond to steroids once the organs involved are identified.
on Panel
Survival Rate*
Treated
(800+ reviews)
How Urgent Is Vasculitis During Immunotherapy?
It depends on what comes with it. A new rash or joint pain alone is reported to your oncology team the same day, but a rash together with sudden numbness, weakness, vision changes, chest pain, palpitations, severe abdominal pain or a marked drop in urine output is a medical emergency — go to the nearest emergency room or call an ambulance immediately, rather than waiting for a clinic appointment.
Go to the ER now, or call an ambulance, if a new rash or unexplained pain comes with any of these:
- Sudden weakness, numbness, difficulty speaking, or vision changes — possible nerve or brain involvement, treat as a stroke emergency
- Chest pain, palpitations, or breathlessness — possible heart-vessel involvement, treat as a cardiac emergency
- Severe abdominal pain, blood in the urine, or a sharp drop in urine output — possible kidney involvement
- A widespread purple or blood-spot rash together with fever
For any other new skin rash, joint pain or unexplained symptom during immunotherapy, call the CION helpline the same day:
Call the CION Helpline Now: 1800 202 8726What Does Immunotherapy-Related Vasculitis Look Like?
It usually starts as a new skin change — small purple or blood-coloured spots (often on the legs), a raised rash that doesn't fade when pressed, or hives that won't clear — sometimes together with joint pain, fever or fatigue. Because vasculitis is rare and its multi-system presentation completes the picture other severe irAE pages don't cover, it's worth knowing what separates an ordinary skin reaction from one that needs review.
| Feature | Ordinary skin irritation or rash | Possible vasculitis — needs review |
|---|---|---|
| Appearance | Flat, red, itchy, fades when pressed | Small purple/blood-coloured spots or raised patches that don't fade when pressed |
| Location | Localised, often where clothing or a product touched skin | Often starts on the lower legs, can spread |
| Accompanying symptoms | Mild itching only | Joint pain, fever, fatigue, or numbness alongside the rash |
| Response to time | Settles within a day or two on its own | Persists, spreads, or is joined by new symptoms |
| Other organs | None affected | May come with kidney, nerve or heart-vessel symptoms |
How Soon After Starting Immunotherapy Can Vasculitis Develop?
Immune-related vasculitis can appear at any point during checkpoint-inhibitor immunotherapy — from the first few weeks to many months into treatment — and, less commonly, even after treatment has finished. This unpredictable timing is why any new rash, joint pain or unexplained organ symptom is reported as soon as it appears, at any stage of treatment, rather than only being watched for in the early cycles.
| Stage | What's typically happening |
|---|---|
| Typically starts | Can begin at any point in treatment — anywhere from the first few weeks to several months in — with no single "usual" window. |
| Early signs | A new rash, joint pain, fever or mild fatigue — easy to mistake for an unrelated skin or joint issue. |
| If unreported | Can progress to kidney, nerve or heart-vessel involvement over days if the affected organs aren't identified early. |
| After stopping treatment | Uncommon, but vasculitis can occasionally appear even after immunotherapy has ended — a new rash post-treatment is still worth reporting. |
There is no safe home-management step for a rash that comes with numbness, weakness, chest symptoms or reduced urine output — those combinations are routed straight to emergency care, without qualification. For a rash or joint pain alone, the correct response is still the same: get it checked the same day, don't wait to see if it settles.
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Mohammed Imran
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Don't Wait Out a New Rash or Unexplained Symptom
Our tumour board includes the same specialists managing your immunotherapy — reach them directly.
Which Organs Can Vasculitis Affect During Immunotherapy?
Vasculitis can affect the skin, joints, nerves, kidneys or heart, and — unlike most immune-related reactions, which usually target one organ — it can involve more than one of these at the same time. This multi-system pattern is what makes it distinct from the single-organ irAEs covered elsewhere on this site.
Skin and joints
The most common presentation — purple or blood-coloured skin spots, a raised rash, and joint pain or swelling. Usually the mildest form and often manageable without stopping immunotherapy.
Kidneys
Can show up as blood in the urine, foamy urine, swelling in the legs, or a sharp drop in how much urine is passed. Needs same-day blood and urine testing.
Nerves
Numbness, tingling, or new weakness in a limb or on one side of the body. Any sudden weakness, numbness or vision change is treated as a stroke emergency, not qualified or watched.
Heart vessels
The rarest but most urgent presentation — chest pain, palpitations or breathlessness. Treated as a cardiac emergency immediately, the same way immune myocarditis is.
How Is Immune Vasculitis Treated?
Treatment starts with confirming which organs are involved through blood tests, urine tests and sometimes a skin or tissue biopsy, then usually begins with corticosteroids to calm the immune reaction. What happens to your immunotherapy schedule depends entirely on which organs are affected.
- 1
Same-day assessment
Blood tests, urine tests and a physical exam identify which organs — skin, kidney, nerve or heart — are involved.
- 2
Confirming the diagnosis
A skin or tissue biopsy may be used to confirm vasculitis and rule out infection or an unrelated skin condition.
- 3
Corticosteroids first
Most cases start on corticosteroids to reduce the inflammation, with the dose and duration set by how many organs are involved.
- 4
Specialist referral where needed
Kidney, nerve or heart involvement brings in a nephrologist, neurologist or cardiologist alongside your oncology team.
- 5
Decision on immunotherapy
Mild, skin-limited vasculitis may allow immunotherapy to continue under closer monitoring; involvement of the kidneys, nerves or heart typically means pausing or stopping it while your tumour board reviews the overall treatment plan.
Rare Reactions Are Manageable When Caught Early
Patients who report a new rash, joint pain or unexplained symptom promptly are supported by the same multidisciplinary team throughout treatment.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Vasculitis on Immunotherapy: Your Questions Answered
What does vasculitis from immunotherapy look like?
It usually starts as a new skin change — small purple or blood-coloured spots (often on the legs), a raised rash that doesn't fade when pressed, or hives that won't clear — sometimes together with joint pain, fever or fatigue. Because vasculitis inflames the blood vessels rather than a single organ, the visible skin change is often the first clue that something wider is happening inside the body, so any unexplained rash of this kind during immunotherapy is checked rather than treated as a routine skin reaction.
Which organs can immunotherapy-related vasculitis affect?
Vasculitis can affect the skin, joints, nerves, kidneys or heart, and — unlike most immune-related reactions, which usually target one organ — it can involve more than one of these at the same time. Skin and joint involvement is the most common and usually the mildest; kidney involvement can show up as blood in the urine or reduced urine output; nerve involvement can cause numbness or weakness; and heart-vessel involvement is the rarest but most urgent presentation.
How is vasculitis during immunotherapy treated?
Treatment starts with confirming which organs are involved through blood tests, urine tests and sometimes a skin or tissue biopsy, then usually begins with corticosteroids to calm the immune reaction. Mild, skin-only vasculitis may allow immunotherapy to continue under closer monitoring, while vasculitis affecting the kidneys, nerves or heart typically means pausing or permanently stopping the immunotherapy responsible while a specialist manages the affected organ.
How urgent is a new rash or unexplained pain during immunotherapy?
It depends on what comes with it. A rash or joint pain alone is reported to your oncology team the same day, but a rash together with sudden numbness, weakness, vision changes, chest pain, palpitations, severe abdominal pain or a marked drop in urine output is a medical emergency — go to the nearest emergency room or call an ambulance immediately rather than waiting for a clinic appointment.
How soon after starting immunotherapy can vasculitis develop?
Immune-related vasculitis can appear at any point during checkpoint-inhibitor immunotherapy — from the first few weeks to many months into treatment — and, less commonly, even after treatment has finished. This unpredictable timing is why any new rash, joint pain or unexplained organ symptom is reported as soon as it appears, at any stage of treatment, rather than only being watched for in the early cycles.
Will vasculitis mean immunotherapy has to stop?
Not always. Mild, skin-limited vasculitis is often manageable with steroids while immunotherapy continues under closer monitoring. When vasculitis affects the kidneys, nerves or heart, most oncology teams pause or permanently stop the immunotherapy responsible until the organ recovers, then review with the tumour board what this means for the overall cancer treatment plan.